Detailed information for compound 28376

Basic information

Technical information
  • TDR Targets ID: 28376
  • Name: 7,8-dimethoxy-1-(3-nitrophenyl)-3,5-dihydro-2 ,3-benzodiazepin-4-one
  • MW: 341.318 | Formula: C17H15N3O5
  • H donors: 1 H acceptors: 3 LogP: 2.39 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1cc2CC(=O)NN=C(c2cc1OC)c1cccc(c1)[N+](=O)[O-]
  • InChi: 1S/C17H15N3O5/c1-24-14-7-11-8-16(21)18-19-17(13(11)9-15(14)25-2)10-4-3-5-12(6-10)20(22)23/h3-7,9H,8H2,1-2H3,(H,18,21)
  • InChiKey: YWIOIQJEZPPBAK-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium ulcerans penicillin-binding lipoprotein 0.0175 0.1252 0.159
Mycobacterium ulcerans penicillin-binding protein PbpA 0.0626 0.5856 0.7619
Mycobacterium tuberculosis Probable penicillin-binding membrane protein PbpB 0.0223 0.1745 0.2934
Trypanosoma cruzi tyrosyl-DNA Phosphodiesterase (Tdp1), putative 0.0065 0.0125 0.5
Leishmania major tyrosyl-DNA phosphodiesterase 1 0.0065 0.0125 1
Mycobacterium ulcerans bifunctional membrane-associated penicillin-binding protein 1A/1B PonA2 0.0288 0.2403 0.3097
Mycobacterium leprae PROBABLE BIFUNCTIONAL PENICILLIN-BINDING PROTEIN 1A/1B PONA1 (MUREIN POLYMERASE) (PBP1): PENICILLIN-INSENSITIVE TRANSGLYCOSYLASE 0.0407 0.3622 0.5147
Mycobacterium tuberculosis Probable bifunctional penicillin-binding protein 1A/1B PonA1 (murein polymerase) (PBP1): penicillin-insensitive transglycosylase 0.0119 0.0685 0.1111
Echinococcus multilocularis tyrosyl DNA phosphodiesterase 1 0.0065 0.0125 1
Trichomonas vaginalis conserved hypothetical protein 0.0407 0.3622 0.5
Mycobacterium ulcerans bifunctional penicillin-binding protein 1A/1B PonA1 0.0407 0.3622 0.4693
Treponema pallidum penicillin-binding protein (pbp-3) 0.0804 0.7675 0.6355
Trypanosoma cruzi tyrosyl-DNA Phosphodiesterase (Tdp1), putative 0.0065 0.0125 0.5
Mycobacterium tuberculosis Probable bifunctional membrane-associated penicillin-binding protein 1A/1B PonA2 (murein polymerase) [includes: penicillin-insen 0.0288 0.2403 0.4065
Trypanosoma brucei tyrosyl-DNA Phosphodiesterase (Tdp1), putative 0.0065 0.0125 0.5
Mycobacterium ulcerans penicillin-binding membrane protein PbpB 0.0804 0.7675 1
Mycobacterium tuberculosis Probable penicillin-binding protein PbpA 0.0626 0.5856 1
Brugia malayi Tyrosyl-DNA phosphodiesterase family protein 0.0065 0.0125 1
Mycobacterium leprae PROBABLE BIFUNCTIONAL MEMBRANE-ASSOCIATED PENICILLIN-BINDING PROTEIN 1A/1B PONA2 (MUREIN POLYMERASE) [INCLUDES: PENICILLIN-INSEN 0.0288 0.2403 0.25
Entamoeba histolytica tyrosyl-DNA phosphodiesterase, putative 0.0065 0.0125 0.5
Loa Loa (eye worm) tyrosyl-DNA phosphodiesterase 0.0065 0.0125 1
Mycobacterium leprae Probable penicillin-binding protein PbpA 0.0626 0.5856 1
Schistosoma mansoni tyrosyl-DNA phosphodiesterase 0.0065 0.0125 1
Treponema pallidum penicillin-binding protein (pbp-1) 0.1032 1 1
Echinococcus granulosus tyrosyl DNA phosphodiesterase 1 0.0065 0.0125 1
Mycobacterium tuberculosis Possible penicillin-binding lipoprotein 0.0175 0.1252 0.2087
Wolbachia endosymbiont of Brugia malayi cell division protein FtsI 0.1032 1 0.5
Mycobacterium leprae Probable penicillin-binding membrane protein PbpB 0.0223 0.1745 0.1071

Activities

Activity type Activity value Assay description Source Reference
ED50 (functional) > 44 mg kg-1 Anticonvulsant activity against clonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 44 mg kg-1 Anticonvulsant activity against tonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 44 mg kg-1 Anticonvulsant activity against clonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 44 mg kg-1 Anticonvulsant activity against tonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 120 uM kg-1 Evaluated for anticonvulsant property in DBA/2 mice against Audiogenic seizures during clonic phase (ip administration) ChEMBL. 11123993
ED50 (functional) > 120 uM kg-1 Evaluated for anticonvulsant property in DBA/2 mice against Audiogenic seizures during tonic phase (ip administration) ChEMBL. 11123993
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against audiogenic seizures in DBA/2 mice (value required to prevent clonic phases of seizures). ChEMBL. 9719593
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against audiogenic seizures in DBA/2 mice (value required to prevent tonic phases of seizures). ChEMBL. 9719593
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against clonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against tonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against audiogenic seizures in DBA/2 mice (value required to prevent clonic phases of seizures). ChEMBL. 9719593
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against audiogenic seizures in DBA/2 mice (value required to prevent tonic phases of seizures). ChEMBL. 9719593
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against clonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 120 uM kg-1 Anticonvulsant activity against tonic phase of the audiogenic seizures in DBA / 2 mice 30 min after ip administration at a dose range 10-120 microM/kg ChEMBL. 9111300
ED50 (functional) > 150 uM kg-1 Anticonvulsant activity against the maximal electroshock in Swiss mice after 45 minutes pretreatment at a dose range 10-150 microM/kg ChEMBL. 9111300
ED50 (functional) > 150 uM kg-1 Pentylenetetrazole-induced seizures in Swiss mice after 45 min pretreatment at a dose range 10-150 microM/kg ChEMBL. 9111300
ED50 (functional) > 150 uM kg-1 Anticonvulsant activity against the maximal electroshock in Swiss mice after 45 minutes pretreatment at a dose range 10-150 microM/kg ChEMBL. 9111300
ED50 (functional) > 150 uM kg-1 Pentylenetetrazole-induced seizures in Swiss mice after 45 min pretreatment at a dose range 10-150 microM/kg ChEMBL. 9111300
ND (functional) 0 Therapeutic index is the ratio between TD50 and ED50 (from the clonic phase of the audiogenic seizures) ; ND means not detectable ChEMBL. 11123993
Rm = -0.181 Relative Lipophilicity measured by reversed-phase high performance thin-layer chromatography (RP-HPTLC) ChEMBL. 11123993
Rm = -0.14 Relative lipophilicity of compound ChEMBL. 9111300
Rm = -0.135 Relative lipophilicity ChEMBL. 9719593
TD50 (functional) > 150 uM kg-1 Evaluated for anticonvulsant property in DBA/2 mice against Locomotion assessed by Rotarod test (ip administration) ChEMBL. 11123993
TD50 (ADMET) > 150 uM kg-1 Motor toxicity in 50% of mice on locomotion assessed by Rotarod test following 30 min ip administration ChEMBL. 9111300

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

3 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.